Probiotic bacteria enhance antigen sampling and processing by dendritic cells in pediatric IBD

Strisciuglio, Caterina; Miele, Erasmo; Giugliano, Francesca Paola; Vitale, Serena; Andreozzi, Marta; Vitale, Alessandra; Cenni, Sabrina; Staiano, Annamaria; Troncone, Riccardo; Gianfrani, C.

doi:10.1016/j.dld.2014.07.052

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…microbiological studies have detected a significant reduction of Bifidobacteria and lactobacilli and an overgrowth of specific pathogenic strains, such as deltaproteobacteria and Bilophila wadsworthia. The use of probiotics in combination with the standard treatment, improves patients' quality of life and life expectancy, reducing significantly clinical symptoms and minimizing side effects [21][22][23][24][25] . The results of our study confirm the beneficial effects of probiotics on Uc activity, partly by improving patient's response to anti-inflammatory treatment.…”

Section: Discussionmentioning

confidence: 99%

The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study

Palumbo¹,

Romeo²,

Gammazza³

et al. 2016

BIOMED PAP

View full text Add to dashboard Cite

Aim.Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs represent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity. Method. Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 patients received a single daily oral administration of mesalazine 1200 mg and a double daily administration of a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4. The treatment was carried out for two years and the clinical response evaluated according to the Modified Mayo Disease Activity Index. Results. All patients treated with combination therapy showed better improvement compared to the controls. In particular, the beneficial effects of probiotics were evident even after two years of treatment. Conclusions. A long-term treatment modality of anti-inflammatory drugs and probiotics is viable and could be an alternative to corticosteroids in mild-to moderate ulcerative colitis.

show abstract

Section: Discussionmentioning

confidence: 99%